Accenture Accelerates and 3 Stock Analyses to Track

Accenture plc (NYSE:ACN) Q4 revenue exceeded expectations and presented higher ¬†FY13 EPS guidance than predicted, causing Argus to be convinced that Accenture’s outsourcing and consulting businesses seem to be in the process of accelerating. The firm keeps a Buy rating and increases its target to $80 from $74 on the stock.

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX): According to Sterne Agee, Allscripts is worth $15 per share, not including $85 million worth in possible cost savings able to be taken out of the business, which possibly would add $4 per share, totaling $19 per share.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is believed by Piper Jaffray to be interested in hiring no one but a bank to explore a sale if all other options fail, since management is not interested in beginning at a bottom. According to Piper, while average takeout multiples in the sector indicate a $22 per share buyout price, Allscripts’s challenges may minimize the takeout price to about $14 per share. The firm continues its caution regarding today’s stock rally after Bloomberg’s report, and it maintains its Neutral rating on the stock.

Monster Worldwide, Inc. (NYSE:MWW) has begun talks with a private equity firm, according to dealReporter.

Investing Insights: Share Buybacks: Apple Kicks Off $10B Repurchase Plan, News Corp. Sells to BSkyB.